(Q26753299)

1

0 references

Ren-Yu Huang

2

0 references

Li-Pai Chen

3

0 references

Zhe-Sheng Chen

4

0 references

Liwu Fu

5

0 references

Ruo-Pan Huang

Biochimica et Biophysica Acta

6

0 references

language of work or name

English

0 references

publication date

April 2016

0 references

published in

0 references

volume

1865

0 references

issue

2

0 references

page(s)

255-65

0 references

cites work

Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Circulating interleukin-6 predicts survival in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf‐1 and Caspase‐9 apoptosome expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Molecular-targeted agents combination therapy for cancer: developments and potentials

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Significance of interleukin-6 (IL-6) in breast cancer (review).

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

The multifaceted roles of chemokines in malignancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

The role of erbB-2 and its ligands in growth control of malignant breast epithelium

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Antibody arrays in biomarker discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

P-glycoprotein in autoimmune rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Adrenomedullin inhibits prostate cancer cell proliferation through a cAMP-independent autocrine mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

The relevance of the TGF-β Paradox to EMT-MET programs

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

The paradoxical role of IL-10 in immunity and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

The evolving war on cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Cancer CXC chemokine networks and tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Chemokines: multiple levels of leukocyte migration control.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Moving targets: Emerging roles for MMPs in cancer progression and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Adrenomedullin prevents apoptosis in prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Tumour stimulating effects of recombinant human interleukin-6

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Cytokines secreted by bone marrow stromal cells protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Stromal fibroblasts in cancer initiation and progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Inflammation meets cancer, with NF-κB as the matchmaker

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Microenvironmental regulation of tumor progression and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Cytokines and their relationship to the symptoms and outcome of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

TGFbeta signalling: a complex web in cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

The diverse and complex roles of NF-κB subunits in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Cancer drug resistance: an evolving paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

VEGF targets the tumour cell

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

The role of tumour-stromal interactions in modifying drug response: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Immunological hallmarks of stromal cells in the tumour microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

NF-κB addiction and its role in cancer: 'one size does not fit all'.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Inflammation, atherosclerosis, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Inhibition of bFGF/EGF-dependent endothelial cell proliferation by the hyaluronan-binding protease from human plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

IL-6: from its discovery to clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Advances in understanding the leukaemia microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

NF-κB and the link between inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Genome-scale CRISPR-Cas9 knockout screening in human cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Mechanisms of cancer drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Bone marrow microenvironment in multiple myeloma progression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Role of interleukin-8 in tumor growth and metastasis of human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

The multiple facets of drug resistance: one history, different approaches

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Targeting the VEGF signaling pathway in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Towards understanding the role of cancer-associated inflammation in chemoresistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Regulation of multidrug resistance by pro-inflammatory cytokines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

New insight into p-glycoprotein as a drug target

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

Mechanisms and insights into drug resistance in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.BBCAN.2016.03.005

7 January 2021

10.1016/J.BBCAN.2016.03.005

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

378541

378541

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference